Hydropothecary (CVE:THCX) Director Michael R. Munzar sold 250,000 shares of the business’s stock in a transaction on Thursday, April 12th. The shares were sold at an average price of C$4.03, for a total transaction of C$1,007,500.00.
Shares of THCX stock opened at C$4.27 on Tuesday. Hydropothecary has a 12-month low of C$1.10 and a 12-month high of C$5.25.
Several equities analysts have recently issued reports on THCX shares. Canaccord Genuity boosted their price target on shares of Hydropothecary from C$5.25 to C$5.75 in a report on Thursday, February 15th. Beacon Securities boosted their price target on shares of Hydropothecary from C$8.50 to C$9.50 and gave the company a “buy” rating in a report on Thursday, April 12th.
ILLEGAL ACTIVITY WARNING: This story was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this story on another publication, it was copied illegally and reposted in violation of United States and international copyright and trademark legislation. The legal version of this story can be accessed at https://www.dispatchtribunal.com/2018/04/17/insider-selling-hydropothecary-thcx-director-sells-250000-shares-of-stock.html.
The Hydropothecary Corporation, together with its subsidiaries, produces and distributes medical marijuana products. The company is headquartered in Gatineau, Canada.
Receive News & Ratings for Hydropothecary Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hydropothecary and related companies with MarketBeat.com's FREE daily email newsletter.